Literature DB >> 12800402

Detecting vulnerable plaque using peripheral blood: inflammatory and cellular markers.

Robert S Schwartz1, Antonio Bayes-Genis, John R Lesser, Massimo Sangiorgi, Timothy D Henry, Cheryl A Conover.   

Abstract

The concept of the vulnerable patient has arrived. Enhanced diagnostic methods will eventually permit accurately finding and treating these patients and their disease. Clinical Cardiologists now recognize that coronary atherosclerosis is two pathophysiologically distinct syndromes: stable and unstable. Stable coronary syndromes result from fixed, severe stenoses limiting blood flow and causing secondary myocardial ischemia. The unstable acute coronary syndromes are frequently catastrophic and are pathophysiologically distinct. They result from different cell subsets causing vascular inflammatory syndromes rather than gradual lumen constriction by plaque. Though pathophysiologically distinct, they may show common pathophysiology when a ruptured plaque heals and progressively becomes a critical stenosis. For the present hs-CRP measurement is the strongest correlative factor for future clinical events due to arterial inflammation: myocardial infarction, unstable angina, stroke, and peripheral vascular disease in both diseased and apparently healthy, asymptomatic patients. The CRP plasma level also is the best risk assessment in patients with either stable or unstable angina, long term after myocardial infarction, and in patients undergoing revascularization therapies. One study showed the only independent cardiovascular risk indicators using multivariate, age adjusted and traditional risk analysis were CRP and Total/HDL cholesterol ratio. If CRP, IL-6, and ICAM-1 levels are added to lipid levels, risk assessment can be improved over lipids alone. The prevalence of high-risk subjects in the general population is low, amplifying diagnostic problems for vulnerable plaque. Since no test yet has high sensitivity or specificity, diagnostic errors are high, with many false positives and negatives. Sensitivity or specificity must be increased by developing a risk marker panel, or by simultaneously finding other markers that themselves are highly sensitive and specific for vulnerable plaque.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12800402     DOI: 10.1034/j.1600-0854.2003.8025.x

Source DB:  PubMed          Journal:  J Interv Cardiol        ISSN: 0896-4327            Impact factor:   2.279


  5 in total

1.  Nitric oxide pretreatment enhances atheroma component highlighting in vivo with intercellular adhesion molecule-1-targeted echogenic liposomes.

Authors:  Patrick H Kee; Hyunggun Kim; Shaoling Huang; Susan T Laing; Melanie R Moody; Deborah Vela; Melvin E Klegerman; David D McPherson
Journal:  Ultrasound Med Biol       Date:  2014-03-05       Impact factor: 2.998

2.  Evaluation of recombinant endostatin in the treatment of atherosclerotic plaques and neovascularization in rabbits.

Authors:  Wei Mao; Jing Kong; Jin Dai; Zhao-quan Huang; Dong-zhi Wang; Gui-bao Ni; Min-li Chen
Journal:  J Zhejiang Univ Sci B       Date:  2010-08       Impact factor: 3.066

3.  Delivery of stem cells to porcine arterial wall with echogenic liposomes conjugated to antibodies against CD34 and intercellular adhesion molecule-1.

Authors:  Stephanie M Herbst; Melvin E Klegerman; Hyunggun Kim; Jiangbo Qi; Harnath Shelat; Michael Wassler; Melanie R Moody; Chen-Min Yang; Xinyi Ge; Yuejiao Zou; Jonathan A Kopechek; Fred J Clubb; Duane C Kraemer; Shaoling Huang; Christy K Holland; David D McPherson; Yong-Jian Geng
Journal:  Mol Pharm       Date:  2010-02-01       Impact factor: 4.939

4.  Early lens aging is accelerated in subjects with a high risk of ischemic heart disease: an epidemiologic study.

Authors:  Line Kessel; Torben Jørgensen; Charlotte Glümer; Michael Larsen
Journal:  BMC Ophthalmol       Date:  2006-04-18       Impact factor: 2.209

Review 5.  Acute phase reactants as novel predictors of cardiovascular disease.

Authors:  M S Ahmed; A B Jadhav; A Hassan; Qing H Meng
Journal:  ISRN Inflamm       Date:  2012-05-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.